1. 167: A phase I/II trial of combination nab-paclitaxel and nintedanib or nab-paclitaxel and placebo in relapsed NSCLC adenocarcinoma (N3). (January 2017) Authors: Tokaca, N.; Espinasse, A.; Petruckevitch, A.; Ellis, S.; Yousaf, N.; Bhosle, J.; O'Brien, M.; Popat, S. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3353 Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse. (September 2015) Authors: Clark, L.; Hepburne-Scott, H.; Ottensmeier, C.; Middleton, M.; Myers, K.A.; Tarlton, A.; Petruckevitch, A.; Bassett, O.; Bonner, P.; Sharma, R.; Nathan, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S686 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Severe vitamin D deficiency associated with BRAF‐mutated melanoma. (1st December 2019) Authors: Fearfield, L.; Nobbs, J.; Petruckevitch, A.; Harland, C. Journal: British journal of dermatology Issue: Volume 181:Number 6(2019) Page Start: 1343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Severe vitamin D deficiency associated with BRAF‐mutated melanoma. (29th September 2019) Authors: Fearfield, L.; Nobbs, J.; Petruckevitch, A.; Harland, C. Journal: British journal of dermatology Issue: Volume 181:Number 6(2019) Page Start: 1343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗